Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 1316390, 6 pages
https://doi.org/10.1155/2018/1316390
Research Article

Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies

1Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego St. 49, 60-355 Poznań, Poland
2Department of Cell Biology, Poznan University of Medical Sciences, Rokietnicka St. 5D, 60-806 Poznań, Poland
3Department of Pharmacology, Poznan University of Medical Sciences, Rokietnicka St. 5A, 60-806 Poznań, Poland
4Department of General Surgery and Multiple Trauma and Division of Gastroenterological and Endocrine Surgery, Provincial Hospital, Juraszów St. 7/19, 60-479 Poznań, Poland

Correspondence should be addressed to Nadia Sawicka-Gutaj; lp.2o@ahyn

Received 13 October 2017; Revised 24 December 2017; Accepted 8 January 2018; Published 6 February 2018

Academic Editor: Fabrizio Montecucco

Copyright © 2018 Nadia Sawicka-Gutaj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. Our aim was to analyze NAMPT expression in thyroid tissue derived from patients with Graves’ disease with (GD) and without (GO) orbitopathy, patients with toxic nodular goiters (TNG) and thyroid cancers (TC), and healthy controls. Methods. 153 thyroid tissue samples of consecutive patients who underwent thyroidectomy were collected. Previous therapy with steroids was an exclusion criterion. We collected clinicopathological data of all subjects and we assessed NAMPT expression using qPCR. Results. We found the highest NAMPT expression in the thyroids of patients with GO ( = 20) and cancers ( = 40). Also, there was statistically significant NAMPT overexpression in patients with TNG ( = 30). Relatively low NAMPT expression was found in GD patients ( = 21) and in the control group ( = 39). In one-way ANCOVA, we confirmed that NAMPT expression differs between subgroups and that it is not influenced by age, BMI, or sex of patients. Conclusions. Reported alteration of NAMPT expression might suggest its involvement in thyroid pathologies. Observed NAMPT overexpression in patients with GO and its relatively low levels in thyroids of patients with GD without eye changes do not confirm causal relationship between NAMPT level and orbitopathy, but this needs further investigation.